MarketCap
Facebook
X
Telegram
Provention Bio Operating Expenses | PRVB
Annual Operating Expenses Provention Bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 141 M | 117 M | 99.7 M | 44.4 M | 26.8 M | 9.14 M | 165 K | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 141 M | 165 K | 62.6 M |
Quarterly Operating Expenses Provention Bio
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 29.8 M | 30.6 M | 29.7 M | - | 27.8 M | 30.2 M | 32.5 M | - | 31.4 M | 22.8 M | 12.9 M | - | 9.97 M | 12.3 M | 11.3 M | - | 5.41 M | 10.2 M | 5.04 M | - | 1.38 M | 3.99 M | - | 165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 32.5 M | 165 K | 17.1 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
31.4 M | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
105 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
34.4 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
308 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
136 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
216 M | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
-3.01 B | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
2.54 B | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
8.51 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
1.72 B | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
77.7 M | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
51.4 M | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
385 M | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
252 M | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
34.3 B | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
4.56 M | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
8.82 M | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
289 M | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
13 M | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
10.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-41 M | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
54.1 B | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
153 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
340 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
22.6 M | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
12.1 M | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
126 M | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
88 M | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
13.6 M | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
13.7 M | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
48.6 B | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
4.15 B | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
77 M | - | -16.42 % | $ 249 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | USA |
 |
Intellia Therapeutics
NTLA
|
441 M | $ 11.18 | -7.72 % | $ 1.21 B | USA |
 |
Novartis AG
NVS
|
25.3 B | $ 163.39 | -0.18 % | $ 317 B | Schweiz |
 |
Omeros Corporation
OMER
|
174 M | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Oramed Pharmaceuticals
ORMP
|
14.5 M | $ 3.97 | -0.75 % | $ 164 M | Israel |
 |
Tyme Technologies
TYME
|
25.5 M | - | 8.07 % | $ 54 M | USA |
 |
Puma Biotechnology
PBYI
|
133 M | $ 8.13 | -3.22 % | $ 407 M | USA |